The Nanopharmaceutical and Regulatory Science group investigates important topics in nanopharmaceuticals and their related regulatory aspects and challenges. We develop and characterize novel nano-based formulations, with the goal of improving the therapeutic index of active pharmaceutical ingredients. In collaboration with other research institutions, we identify and investigate critical quality attributes of nanopharmaceuticals and nanosimilars, such as mechanisms of action, safety, and practical application issues. We also interface with the pharmaceutical industry and regulatory authorities to establish science-based guidelines on safe and correct use of nanopharmaceuticals and nanosimilars.
Prof. Dr. Scott McNeil
Nanopharmaceutical & Regulatory Sciences
Tel: +41 61 207 64 04